Assessment of Intermingled Phlegm and Blood Stasis Syndrome in Coronary Heart Disease: Development of a Diagnostic Scale
Table 1
Demographics of the study participants.
IPBSS
Non-IPBSS
Overall population
(n = 729)
(n = 413)
(n = 1142)
Gender
Male
460 (63.1)
240 (58.1)
700 (61.3)
Age
≤40
8 (1.1)
2 (0.5)
10 (0.9)
≤60
176 (24.1)
85 (20.6)
261 (22.9)
≤80
472 (64.8)
263 (63.6)
735 (64.4)
>80
73 (10)
63 (15.3)
136 (11.9)
Co-morbidities
Hypertension
518 (71.1)
281 (68.03)
799 (70.0)
T2DM
207 (28.4)
139 (33.7)
346 (30.3)
Hyperlipidemia
113 (15.5)
60 (14.5)
173 (15.1)
Cerebral infarction
70 (9.6)
62 (15.0)
132 (11.6)
Gastritis
60 (8.2)
46 (11.1)
106 (9.23)
Arrhythmias
48 (6.6)
42 (10.2)
90 (7.9)
Lung infection
39 (5.3)
33 (8.00)
72 (6.3)
COPD
35 (4.8)
21 (5.08)
56 (4.9)
Hyperuricemia
29 (4.0)
18 (4.36)
47 (4.1)
Atherosclerosis
26 (3.6)
21 (5.08)
47 (4.1)
T2DM, type 2 diabetes mellitus; COPD, chronic obstructive pulmonary disease; IPBSS, Intermingled Phlegm and Blood Stasis Syndrome. All comorbidities were diagnosed according to the International Statistical Classification of Diseases and Related Health Problems 10th Revision (ICD-10).
